1. Search Result
Search Result
Results for "

Programmed death-ligand 1 (PD-L1)

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

3

Peptides

7

Inhibitory Antibodies

2

Natural
Products

11

Recombinant Proteins

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128605

    PD-1/PD-L1 Cancer
    PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC50 of 92.3 nM .
    PD-1-IN-22
  • HY-138139A

    T785 hydrochloride

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
    AXC-715 hydrochloride
  • HY-138139B

    T785 trihydrochloride

    Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist. AXC-715 trihydrochloride can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
    AXC-715 trihydrochloride
  • HY-P9904
    Atezolizumab
    25+ Cited Publications

    MPDL3280A

    PD-1/PD-L1 Apoptosis Autophagy Cancer
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
    Atezolizumab
  • HY-P3440

    Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1 Cancer
    WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .
    WL12
  • HY-N0596

    20(R)-Panaxadiol

    PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT Cancer
    Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .
    Panaxadiol
  • HY-P99723

    BCD-135

    PD-1/PD-L1 Cancer
    Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .
    Manelimab
  • HY-151066

    PD-1/PD-L1 Cancer
    BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model .
    BMS-1233
  • HY-158052

    PD-1/PD-L1 Cancer
    PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC50 of 23.78 nM .
    PD-1/PD-L1 antagonist 1
  • HY-P10950

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
    PD-L1 inhibitory peptide
  • HY-N0596R

    PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT Cancer
    Panaxadiol (Standard) is the analytical standard of Panaxadiol. This product is intended for research and analytical applications. Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .
    Panaxadiol (Standard)
  • HY-P991148

    PD-1/PD-L1 Cancer
    Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .
    Moflerafusp alfa
  • HY-P99052
    Tislelizumab
    2 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
    Tislelizumab
  • HY-P99114

    PD-1/PD-L1 Cancer
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
    Sugemalimab
  • HY-P10439

    PD-1/PD-L1 Inflammation/Immunology Cancer
    CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .
    CVRARTR
  • HY-P991154

    VEGFR PD-1/PD-L1 Cancer
    Pumitamig is a humanized bispecific immunoglobulin (H-γ1-VH_L-κ) dimer antibody targeting human vascular endothelial growth factor A (VEGFA) and human programmed death ligand 1 (PD-L1). Pumitamig is promising for research of various solid tumors .
    Pumitamig
  • HY-P991151

    PD-1/PD-L1 TNF Receptor Cancer
    Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
    Opamtistomig

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: